ORXES

FIRST-IN-CLASS Novel Therapies For

Resistant Hypertension （RH）
Pulmonary Hypertension（PH）
Premature Ejaculation （PE）
Ischemic Stroke（IS），etc.

FIRST-IN-CLASS Novel Mechanisms

Novel Compound，Triple-Target RH Candidate
Multi-Target，Ameliorable PH Candidate
Second Potential NME PE Drug Globally
Extended Treatment Windows IS Candidate

Great Market Demand

Hypertension-Over￥100bn Market, 340m Patients
PH-over ￥10bn Market
PE-150m Patients in China，Great Demand
IS- Cause Most Deaths in China，As NBP Has￥10bn Sales